Positive Correlation With Patient-Reported Outcomes Seen in Phase III ENLIVEN Trial
January 24th 2019Hans Gelderblom, MD, PhD, discusses the correlation between the overall response rate by Tumor Volume Score and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.